Can the immune system be boosted against Staphylococcus aureus by delivery of messenger RNA?
Staphylococcus aureus is a feared pathogen (MRSA, multi-resistant S. aureus) due to frequent resistances against many antibiotics, especially in hospital infections. Researchers at the Paul-Ehrlich-Institut have identified immunological processes that prevent a successful immune response directed against the pathogenic agent.
Annual Report 2015/16 of the Paul-Ehrlich-Institut published
Biomedicines are undergoing a rapid development – this is accompanied by the scientific and regulatory activities of the Paul-Ehrlich-Institut as a leading medicines authority in Europe. The Annual Report 2015/16 provides information on the strategy, marketing authorisation, testing and current research activities at the PEI in a national, European, and world-wide setting.
VAC2VAC – Vaccine batch to vaccine batch comparison by consistency testing
After the VAC2VAC project was started in March 2016, the first annual meeting was held at the Paul-Ehrlich-Institut on 9 and on 10 March 2017. VAC2VAC is a consortium composed of both public and private members. It consists of 20 partners including pharmaceutical manufacturers of vaccines for human and veterinary use, academic institutes, and regulatory authorities.